The ADHD treatment developer raised $27 million in its IPO in May.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
Alcobra Pharmaceuticals Ltd. (Nasdaq: ADHD) raised a gross $33 million in its secondary offering on Thursday. The company issued two million shares at $16.50 per share. The underwriters, Stifel Nicolaus, Aegis Capital Corp., JMP Securities have a 30-day option to buy additional 300, 000 shares. Alcobra will use the proceeds for the development of its proprietary drug, MG01CI (Metadoxine extended-release), for the treatment of ADHD and Fragile X Syndrome, a factor in autism.
Alcobra raised $27 million in its IPO in May.
Alcobra’s share price closed at $17.01 on Friday, giving a market cap of $189 million, after falling 0.5% during the session.
Published by www.globes-online.com